Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
7-10 Yr Trsy Ishares | IEF | Nov 13, 2024 | 93.29 | -0.06 |
89bio | ETNB | Nov 13, 2024 | 8.91 | -1.49 |
8x8 | EGHT | Nov 13, 2024 | 2.88 | +0.70 |
908 Devices | MASS | Nov 13, 2024 | 2.34 | -19.86 |
99 Acquisition Group | NNAGU | Nov 13, 2024 | 10.60 | 0.00 |
9F ADR | JFU | Nov 13, 2024 | 1.40 | -2.78 |
A SPAC II Acquisition | ASCB | Nov 13, 2024 | 11.19 | 0.00 |
A-Mark Precious Metals | AMRK | Nov 13, 2024 | 30.25 | -0.62 |
a.k.a Brands | AKA | Nov 13, 2024 | 20.42 | -2.67 |
A.O Smith | AOS | Nov 13, 2024 | 73.11 | -0.04 |
A10 Networks | ATEN | Nov 13, 2024 | 16.52 | -0.96 |
A2Z Cust2Mate Solutions | AZ | Nov 13, 2024 | 6.42 | -0.47 |
AA Mission Acquisition | AAM | Nov 13, 2024 | 10.05 | 0.00 |
AAA - A Rated Corporate Bond Ishares | QLTA | Nov 13, 2024 | 47.33 | -0.27 |
Aadi Bioscience | AADI | Nov 13, 2024 | 2.17 | 0.00 |
AAON | AAON | Nov 13, 2024 | 134.63 | -2.25 |
AAR | AIR | Nov 13, 2024 | 68.32 | +0.68 |
Abacus Life | ABL | Nov 13, 2024 | 8.75 | +6.45 |
Abbott Laboratories | ABT | Nov 13, 2024 | 115.74 | -0.60 |
AbbVie | ABBV | Nov 13, 2024 | 170.35 | -0.43 |
AbCellera Biologics | ABCL | Nov 13, 2024 | 2.92 | -1.35 |
Abeona Therapeutics | ABEO | Nov 13, 2024 | 6.10 | -0.08 |
Abercrombie & Fitch | ANF | Nov 13, 2024 | 141.73 | +1.29 |
Aberdeen Asia-Pacificome Fund | FAX | Nov 13, 2024 | 15.98 | -2.50 |
Aberdeen Australia Equity Fund | IAF | Nov 13, 2024 | 4.50 | -0.22 |
Aberdeen Emerging Markets Fund | AEF | Nov 13, 2024 | 5.27 | -0.34 |
Aberdeen Global Fund | FCO | Nov 13, 2024 | 6.01 | +0.50 |
Aberdeen Global Infrastructure | ASGI | Nov 13, 2024 | 19.11 | -0.47 |
Aberdeen Income Credit Strategies Fund | ACP | Nov 13, 2024 | 6.49 | -0.92 |
Aberdeen Income Credit Strategies Pref | ACP-A | Nov 13, 2024 | 23.97 | +1.14 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.